PE20221005A1 - Derivados de la camptotecina - Google Patents
Derivados de la camptotecinaInfo
- Publication number
- PE20221005A1 PE20221005A1 PE2022000046A PE2022000046A PE20221005A1 PE 20221005 A1 PE20221005 A1 PE 20221005A1 PE 2022000046 A PE2022000046 A PE 2022000046A PE 2022000046 A PE2022000046 A PE 2022000046A PE 20221005 A1 PE20221005 A1 PE 20221005A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- present
- formula
- camptothecin derivatives
- provides
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
- 108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion proporciona un compuesto de Formula I, o una sal farmaceuticamente aceptable del mismo, en donde: X es -NH-, -O- o -CH2-; Y es -NH-, -O- o -CH2-; Z esta ausente, -NH- o -N(alquilo C1-3)-; y n es un numero entero seleccionado entre 0 o 1. Estos compuestos son utiles en el tratamiento de enfermedades mediadas por la enzima topoisomerasa I, como los canceres. La presente invencion tambien proporciona procesos para la preparacion de compuestos de Formula I. Los compuestos de la presente invencion son mas solubles en agua, estables en solucion tampon a varios pH, y presentan una mejor actividad antitumoral y una rapida liberacion de SN-38 en los microambientes tumorales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921027783 | 2019-07-11 | ||
| PCT/IB2020/056580 WO2021005583A1 (en) | 2019-07-11 | 2020-07-13 | Camptothecin derivatives with a disulfide moiety and a piperazine moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221005A1 true PE20221005A1 (es) | 2022-06-15 |
Family
ID=71670329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000046A PE20221005A1 (es) | 2019-07-11 | 2020-07-13 | Derivados de la camptotecina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220242874A1 (es) |
| EP (1) | EP3997094A1 (es) |
| CN (1) | CN114341141A (es) |
| AU (1) | AU2020309244A1 (es) |
| BR (1) | BR112022000401A2 (es) |
| CA (1) | CA3146510A1 (es) |
| CL (1) | CL2022000045A1 (es) |
| IL (1) | IL289677A (es) |
| MX (1) | MX2022000474A (es) |
| PE (1) | PE20221005A1 (es) |
| PH (1) | PH12022550050A1 (es) |
| WO (1) | WO2021005583A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022153211A1 (en) * | 2021-01-13 | 2022-07-21 | Sun Pharma Advanced Research Company Limited | Liposomal composition of a camptothecin derivative |
| CN119823140B (zh) * | 2025-01-13 | 2025-11-14 | 重庆医科大学 | 一种gsh响应型西达本胺异二聚体纳米前药及其制备方法与应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350756B1 (en) | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
| AU2002366100A1 (en) | 2001-11-20 | 2003-06-10 | University Of Kentucky Research Foundation | Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins |
| ITRM20020306A1 (it) | 2002-05-31 | 2003-12-01 | Sigma Tau Ind Farmaceuti | Esteri in posizione 20 di camptotecine. |
| TW200616604A (en) * | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| US7875602B2 (en) | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
| DK2396036T3 (en) | 2009-02-13 | 2017-10-16 | Immunomedics Inc | Immune conjugates with an intracellular cleavable compound |
| WO2012067670A1 (en) | 2010-11-18 | 2012-05-24 | Saladax Biomedical Inc. | Irinotecan immunoassay |
| CN102850400A (zh) | 2011-06-30 | 2013-01-02 | 周文强 | 喜树碱衍生物及其制备方法、药物组合物与用途 |
| CN102516258B (zh) | 2011-11-11 | 2014-06-25 | 正大天晴药业集团股份有限公司 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
| CN103508981A (zh) | 2012-06-18 | 2014-01-15 | 北京美倍他药物研究有限公司 | 新的哌嗪衍生物及其医药用途 |
| KR20140010517A (ko) | 2012-07-12 | 2014-01-27 | 고려대학교 산학협력단 | 약물 전달 및 세포내 흡수의 직접 모니터링이 가능한 약물전달 복합체 및 그 제조방법 |
| US9150585B2 (en) | 2012-11-13 | 2015-10-06 | Fl Therapeutics Llc | Analogs of camptothecin |
| US10098967B2 (en) | 2012-12-03 | 2018-10-16 | Ohio State Innovation Foundation | Self-assembly of therapeutic agent-peptide nanostructures |
| CN104370862B (zh) | 2013-08-13 | 2019-04-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 水溶性抗肿瘤化合物 |
| CN103524519B (zh) | 2013-09-24 | 2015-06-24 | 中国科学技术大学 | 喜树碱前药单体及其聚合前药两性分子、以及它们的制备和用途 |
| CN103552010A (zh) | 2013-11-07 | 2014-02-05 | 凡嘉科技（无锡）有限公司 | 一种爬片皿专用镊子 |
| WO2015178265A1 (ja) | 2014-05-23 | 2015-11-26 | 日本化薬株式会社 | 新規なグルタミン酸誘導体およびその用途 |
| CN104306332B (zh) | 2014-09-24 | 2017-02-15 | 东南大学 | 一种喜树碱类磷脂化合物、其药物组合物及应用 |
| CN104368011B (zh) | 2014-11-27 | 2017-05-10 | 东南大学 | 一种药物甜菜碱缀合物、其药物组合物及应用 |
| JP6323406B2 (ja) * | 2015-07-27 | 2018-05-16 | トヨタ自動車株式会社 | 内燃機関の制御装置 |
| CN105131039B (zh) | 2015-09-18 | 2017-09-15 | 东南大学 | 一种喜树碱类磷脂化合物、其药物组合物及应用 |
| CN105457038A (zh) | 2015-11-09 | 2016-04-06 | 东南大学 | 一种速释型药物磷脂化合物及其药物组合物 |
| US20200078468A1 (en) * | 2016-04-13 | 2020-03-12 | Tarveda Therapeutics, Inc. | Neurotensin receptor binding conjugates and formulations thereof |
| WO2017210246A2 (en) * | 2016-05-31 | 2017-12-07 | Tarveda Therapeutics, Inc. | Penicillamine conjugates and particles and formulations thereof |
| CN106046029B (zh) | 2016-06-01 | 2019-01-22 | 西南大学 | 一类还原性响应两亲性小分子前药及其制备方法 |
| CN106620717B (zh) | 2016-12-13 | 2020-11-24 | 上海交通大学 | 一种具有逆转肿瘤多药耐药性功能的两亲性缀合物抗肿瘤纳米药及其制备方法和应用 |
| CN106967081A (zh) | 2017-03-17 | 2017-07-21 | 南开大学 | 一种具有化疗增敏作用的诊疗一体化药物的合成方法 |
| CN106946899B (zh) | 2017-03-21 | 2018-11-23 | 莎穆(上海)生物科技有限公司 | 一种喜树碱类前药及其制备和应用 |
| CN106916236B (zh) | 2017-03-27 | 2019-04-09 | 莎穆(上海)生物科技有限公司 | 一种环糊精-喜树碱类超分子化疗药物及其制备和应用 |
| CN108785683A (zh) | 2017-04-27 | 2018-11-13 | 西南大学 | 一种还原响应性药物-药物共轭体的制备方法 |
| CN108409756B (zh) | 2018-03-08 | 2019-12-10 | 莎穆(上海)生物科技有限公司 | 一种基于喜树碱类的异二聚体多功能前药及其制备方法和应用 |
| CN108586535A (zh) | 2018-07-03 | 2018-09-28 | 哈尔滨理工大学 | 含喜树碱结构的磷脂类似物、制备方法及用途 |
-
2020
- 2020-07-13 EP EP20742937.4A patent/EP3997094A1/en not_active Withdrawn
- 2020-07-13 PE PE2022000046A patent/PE20221005A1/es unknown
- 2020-07-13 MX MX2022000474A patent/MX2022000474A/es unknown
- 2020-07-13 AU AU2020309244A patent/AU2020309244A1/en not_active Abandoned
- 2020-07-13 PH PH1/2022/550050A patent/PH12022550050A1/en unknown
- 2020-07-13 CA CA3146510A patent/CA3146510A1/en active Pending
- 2020-07-13 WO PCT/IB2020/056580 patent/WO2021005583A1/en not_active Ceased
- 2020-07-13 BR BR112022000401A patent/BR112022000401A2/pt not_active Application Discontinuation
- 2020-07-13 CN CN202080054984.5A patent/CN114341141A/zh active Pending
- 2020-07-13 US US17/625,960 patent/US20220242874A1/en not_active Abandoned
-
2022
- 2022-01-06 IL IL289677A patent/IL289677A/en unknown
- 2022-01-07 CL CL2022000045A patent/CL2022000045A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022550050A1 (en) | 2022-11-07 |
| EP3997094A1 (en) | 2022-05-18 |
| CL2022000045A1 (es) | 2022-11-04 |
| CA3146510A1 (en) | 2021-01-14 |
| MX2022000474A (es) | 2022-03-11 |
| IL289677A (en) | 2022-03-01 |
| AU2020309244A1 (en) | 2022-03-03 |
| CN114341141A (zh) | 2022-04-12 |
| WO2021005583A1 (en) | 2021-01-14 |
| BR112022000401A2 (pt) | 2022-03-29 |
| US20220242874A1 (en) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022500032A1 (en) | Conjugates of a cell-binding molecule with camptothecin analogs | |
| PE20221910A1 (es) | Derivados de pirazolilo utiles como agentes anticancerigenos | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| MX2021011242A (es) | Conjugados de vesícula extracelular y usos de estos. | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| AR022860A1 (es) | Derivados de camptotecina que poseen actividad antitumoral | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| JOP20210171A1 (ar) | مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان | |
| ECSP003637A (es) | Inhibidores triciclicos de poli (adp-ribosa) polimerasas | |
| MX2022009534A (es) | Inhibidores de ectonucleotido pirofosfatasa/fosfofiesterasa 1 (enpp1) y metodos de uso de los mismos. | |
| AR034270A1 (es) | 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| AR023574A1 (es) | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios | |
| UY26332A1 (es) | Nuevos derivados del ácido aminodicarboxílico con propiedades farmacéuticas. | |
| PE20221005A1 (es) | Derivados de la camptotecina | |
| EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
| ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| AR123049A1 (es) | Compuestos terapéuticos y modos de uso | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| DE60320398D1 (de) | Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs | |
| AR044083A1 (es) | Compuestos con actividad anti-inflamatoria | |
| BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
| CO2024000083A2 (es) | Pirrolo[2,3-d]pirimidinas sustituidas, su preparación y su aplicación terapéutica | |
| ATE424200T1 (de) | Solubilisierte topoisomerase-gift-mittel | |
| ES2981659T3 (es) | Compuestos, composiciones y métodos de imidazo[4,5-c]quinolina sustituidos por alquil éter ramificado n-1 |